Evidence map›Paper›PMID 39406925›Full record

ArticleScientific reports2024

New insight into a simple high-yielding method for the production of fully folded and functional recombinant human CCL5.

Afzaal Tufail, Saeed Akkad, Amanda R Noble, Martin A Fascione, Nathalie Signoret

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Afzaal TufailHull York Medical School, University of York, York, YO10 5DD, UK.
Saeed AkkadDepartment of Chemistry, University of York, York, YO10 5DD, UK.
Amanda R NobleDepartment of Chemistry, University of York, York, YO10 5DD, UK.
Martin A FascioneDepartment of Chemistry, University of York, York, YO10 5DD, UK.
Nathalie SignoretHull York Medical School, University of York, York, YO10 5DD, UK. nathalie.signoret@york.ac.uk.

Funding

EPSRC EP/K039660/1UKRI: Horizon Europe Guarantee Consolidator award EP/X023680/1
6 · The paper itself

Abstract

Chemokines are proteins important for a range of biological processes from cell-directed migration (chemotaxis) to cell activation and differentiation. Chemokine C-C ligand 5 (CCL5) is an important pro-inflammatory chemokine attracting immune cells towards inflammatory sites through interaction with its receptors CCR1/3/5. Recombinant production of large quantities of CCL5 in Escherichia coli is challenging due to formation of inclusion bodies which necessitates refolding, often leading to low recovery of biologically active protein. To combat this, we have developed a method for CCL5 production that utilises the purification of SUMO tagged CCL5 from E. coli SHuffle cells avoiding the need to reform disulfide bonds through inclusion body purification and yields high quantities of CCL5 (~ 25 mg/L). We demonstrated that the CCL5 produced was fully functional by assessing well-established cellular changes triggered by CCL5 binding to CCR5, including receptor phosphorylation and internalisation, intracellular signalling leading to calcium flux, as well as cell migration. Overall, we demonstrate that the use of solubility tags, SHuffle cells and low pH dialysis constitutes an approach that increases purification yields of active CCL5 with low endotoxin contamination for biological studies.

Indexed as

Chemokine CCL5Escherichia coliReceptors, CCR5Recombinant ProteinsCell MovementHumansPhosphorylationProtein FoldingCCL5 protein, humanCCR5 protein, humanChemokine CCL5Receptors, CCR5Recombinant ProteinsCCL5CCR5Chemokine activity testingProtein purificationRecombinant chemokine production

Identifiers

PMID39406925
PMCPMC11480376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.